GSK plc (GSK) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 25 wire items for GSK, including 16 SEC filings, 7 press releases and news items and 2 analyst ratings. The most recent was published Nov 6, 2026.

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK rankings

Financial highlights

Full financials
Revenue, FY2025
£32.67B
Revenue growth
+4.1%
Net income, FY2025
£5.72B
Net margin
17.5%
Free cash flow, FY2025
£6.39B
Cash
£3.40B

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

News · 26 weeks117+83%
2026-05-10: 52026-05-17: 72026-05-24: 52026-05-31: 22026-06-07: 72026-06-14: 62026-06-21: 62026-06-28: 32026-07-05: 42026-07-12: 72026-07-19: 62026-07-26: 52026-08-02: 12026-08-09: 42026-08-16: 12026-08-23: 52026-08-30: 22026-09-06: 72026-09-13: 42026-09-20: 32026-09-27: 12026-10-04: 42026-10-11: 52026-10-18: 52026-10-25: 62026-11-01: 6
2026-05-102026-11-01
Mix5390d
  • SEC Filings38(72%)
  • Other10(19%)
  • Analyst4(8%)
  • Offering1(2%)

Latest news

25 items

GSK FAQ

11 questions
  • What does GSK plc do?
    GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system...
  • What is the latest news on GSK?
    In the last 30 days Quantisnow tracked 25 wire items for GSK: 16 SEC filings, 7 press releases and news items and 2 analyst ratings. The most recent was published on November 6, 2026.
  • What is GSK revenue?
    GSK plc (GSK) reported £32.67B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 4.1% from the year before.
  • Is GSK profitable?
    Yes. GSK plc earned £5.72B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 17.5%.
  • How much cash and debt does GSK have?
    GSK plc reported £3.40B in cash and cash equivalents and £14.71B of debt on its most recent balance sheet in SEC filings.
  • Where does GSK stock trade?
    GSK plc (GSK) is listed on NYSE.
  • What sector and industry is GSK in?
    GSK plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did GSK plc go public?
    GSK plc (GSK) completed its IPO in 2022.
  • What are analysts saying about GSK?
    Across the last 8 analyst actions on GSK plc, there were 2 upgrades and 2 downgrades. The most recent action was from Jefferies: Hold with a $55.90 price target on 2026-10-29. Recent price targets range from $55.90 to $70.00.
  • What companies are similar to GSK?
    Notable peers in the same industry include JNJ (Johnson & Johnson), NVS (Novartis AG), AZN (AstraZeneca PLC), SNY (Sanofi). Compare GSK side-by-side with any of them on Quantisnow.
  • How can I track GSK on Quantisnow?
    Quantisnow aggregates GSK plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GSK to receive live email and push alerts on every new disclosure.